NZ236280A

NZ236280A - Transdermal delivery system for administering pharmacological compounds under ph-control

Info

Publication number: NZ236280A
Application number: NZ236280A
Authority: NZ
Inventors: Arun Rajaram Gupte; Uwe Rohr; Bernd Zierenberg
Original assignee: Boehringer Ingelheim Int
Priority date: 1989-12-01
Filing date: 1990-11-29
Publication date: 1994-06-27
Also published as: GR3032175T3; EP0456792B1; EP0456792A1; NO912985D0; KR920700704A; PT96045B; DE3939703C2; PT96045A; AU637861B2; DK0456792T3; IL96506A; FI107707B; AU6875791A; RU1834665C; CA2046337C; HUT59615A; WO1991007998A1; KR0143549B1; IE904322A1; DE59010885D1

Abstract

The invention concerns the improved transdermal application of pharmacologically active compounds.

Description

<div class="application article clearfix" id="description"> 236280 ! c2v,tV: A'.X&tt ! 1 c :jCC-. . tv. ,r . CI i'.'u-'-'I ! Btoifcft^cv.• BW-weIW*. . p.,. ,. 2 7 JUNTO Publico^: on D<?ts: P.O. Journr!, :::: >. /3SI/. Patents Form No. 5 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION TRANSDERMAL SYSTEM FOR ADMINISTERING PHARMACOLOGICAL COMPOUNDS UNDER PH-CONTROL WE, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, a body corporate under the laws of the Federal Republic of Germany of D-6507 Ingelheim am Rhein, FEDERAL REPUBLIC OF GERMANY hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: - 1 - (followed by page la) N.Z. PATEislT OF PICE 29 NOV 1990 RECEIVED - la - 23(>:i80 56177000.319 "Transdermal system for administering pharmacological compounds under pH-control" 5 The invention relates to an improved transdermal system. More particularly it relates to a transdermal system in the form of a plaster for the administration of pharmacologically active substances under pH-controlled conditions. 10 The transdermal administration of pharmacologically active compounds to animals, especially humans, using transdermally therapeutic systems has been known in the prior art for some time. Suitable plasters for this purpose are disclosed for example in US Patent 3558122 15 and 3558123. Although in these and numerous subsequent patent applications a number of active substances are shown to be suitable, it has been found in practice that unexpected problems may occur when they are used on patients even if tests carried out in vitro have already 20 demonstrated that the plaster containing the active substance will release the active substance in sufficient quantities. However, when the theory was put into practice on humans, the sufficiently high or constant blood level 25 values expected could not be achieved. Thus, for example, clenbuterol is used orally in the form of tablets or syrups as a /^-sympathomimetic for treating bronchial asthma. Contrary to expectation, the transdermal administration of clenbuterol has not 30 hitherto resulted in constant blood level values. It has been found, surprisingly, that the flux rate for the active substance in the transdermal administration of, for example, clenbuterol can be crucially improved if the pH of the skin surface is 3 5 maintained at a constant level between 6.0 and 8.5. In one aspect, therefore, the invention provides a transdermal therapeutic delivery system comprising a plaster having a backing layer impervious to a \ 1 1 J(JN 1992 ^ 'I ^ P i V c <Vv 23(i280 2 therapeutically active substance, a reservoir of active substance situated, or adapted to be situated, between the backing layer and the skin and a means for securing the plaster on the skin, and in which at least one 5 pharmacologically acceptable additive capable of adjusting the pH of the skin surface to a desired predeterminable value is present. In another aspect, the invention provides a method of administering transdermally a pharmacologically active 10 substance in which the pH value of the skin surface is maintained substantially constant within a predetermined range which includes the range over which the flux rate [>g/cm2h] of the active substance is at a maximum. 15 skin is defined as the quantity of active substance per unit of area of the skin and per unit of time and is normally given in [nq/cm2. h] . The flux rate for clenbuterol, for example, reaches a maximum in the pH range specified above, but decreases sharply at higher 20 and lower pH levels. The pH level of the skin surface differs between individual people and at different times. A pH level of 5.5 to 6.0, taken as standard, will fluctuate in individual cases between pH 4.5 and 8.0 and will depend 25 on a number of different factors. Fluctuations in the pH level may be caused on the one hand by the plaster itself and on the other hand by the active substance. As can be seen from the graph below, the flux rate of clenbuterol is reduced drastically outside the pH range specified, 30 with the result that it is no longer guaranteed that the skin will be sufficiently permeable to clenbuterol. The invention therefore includes transdermal systems which make it possible to achieve a substantially constant.pH level on the skin and thus allow active 35 substances to diffuse through the skin in the range of their maximum flux rate. The flux rate of an active substance through the Such systems may be constructed by havin« nn t-hp side which comes into contact with the skin, 236 - 3 - substance (additive) which buffers the pH value on the surface of the skin in the desired area. Obviously, the substances or mixtures of substances involved must be pharmacologically acceptable. For achieving a pre-5 determined pH value on the skin, it is appropriate to use additives such as, for example, weak bases, weak acids, organic and inorganic salts which form a buffer system with the skin surface, or buffer mixtures (buffer systems). 10 The quantity of additives should not be too small, so as to ensure that the pH value on the surface of the skin can be adjusted to the desired level for the entire period of time that the plaster is worn. The quantity of additive is generally between 2 and 15 10% by weight, based on the weight of the active substance reservoir of the transdermal system, whilst a range between 4 and 6% by weight is preferred. This quantity of additive is sufficient to adjust and control the pH of the skin to a predetermined level 2 0 for a period of 1 to 7 days. One advantage of such an adjustment of the pH value is that basic active substances which set up a basic pH level on the skin surface are able to shift the pH of the skin into the acid range by the addition of acid salts. 25 In this way, the acceptability of transdermal systems can be improved substantially, since the growth of bacteria in the acid pH range is substantially reduced. Another advantage of adjusting the pH on the surface of the skin is the fact that slightly acidic or basic 3 0 active substances will form a buffer system by the addition of suitable salts and a defined pH will be obtained, so that suitable fluctuations in the pH of the skin surface can be balanced out. Suitable salts or weak acids which are suitable as 3 5 additives for adjusting the pH include, for example the following: disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium acetate, potassium dihydrogen phosphate, sodium 236280 - 4 - carbonate, sodium hydrogen carbonate, boric acid, sodium borate, citric acid, sodium or potassium citrate, monocalcium orthophosphate (Ca (H2P04)2), potassium hydrogen phosphate, dipotassium hydrogen phosphate, 5 tartaric acid, potassium or sodium tartrate, sodium hydrogen phthalate. Buffer systems and buffer mixtures with which a pH value of between 3 and 10 can be achieved, this being the overall desired range, are sufficiently well known from 10 the prior art. The following are examples of active substances the diffusion characteristics of which can be changed by adjusting the pH: physostigmine, clonidine, fentanyl, N-(2-methoxyethyl)-15 noroxymorphone, ephedrine, nicotinicacidamide, clenbuterol, pramipexol, lisuride, terbutaline, salbutamol, hexoprenaline, insulin, vasopressin, atrial natriuretic peptide (ANP). The advantages and findings according to the 20 invention can also be applied to other active substances occurring in the form of weak basis or weak acids. A delivery system according to the invention in the form of a plaster may also advantageously be used to make the pH of the skin surface slightly acidic (pH = 5.5 to 25 6.9), so as to avoid undesirable bacterial growth and possible skin irritations resulting from it. Neutral molecules the flux rates of which are either unaffected or only slightly affected by the pH of the skin are particularly suitable for this purpose e.g. 30 nitroglycerine. Transdermal delivery systems suitable for use in conjunction with additives for adjustment of the pH value are known from the prior art. Generally, they are matrix systems of one of the polymers or copolymers listed 35 below. polymethacrylate, polyvinylpyrrolidone, ethylcellulose, hydroxypropylmethylcellulose phthalate, polyvinylalcohol or copolymers thereof with vinyl laurate 2362 8 - 5 - or maleic acid, vinyl acetate or copolymers thereof with vinyl laurate, or maleic acid, vinyl acetate or copolymers thereof with vinyl laurate or maleic acid, polyvinylether, butyl rubber and polycaprolactam. 5 Preferred polymers and copolymers are those produced by emulsion polymerisation. With polymers of this kind, it is known that the release of active substance can be adjusted by varying the particle size of the polymer particles, by varying the layer thickness in the range 10 between 40 and 200 /xm, preferably up to 140 /xm, and by varying the glass transition temperature. The particle size relates to the particle diameter of the polymeric material after it has been produced and may be up to 500 /zm. The particle size (diameter) can be 15 adjusted depending on the conditions of polymerisation. A reduction in the particle size results in an increase in the rate of release. The glass transition temperature can be adjusted by changing the monomer composition and is, for example, 20 between -20° and +80°C, preferably between -20° and + 400C, particularly preferably between -10° and +30°C. An increase in the glass transition temperature is connected with a lowering of the rate of release. Using the emulsion polymerisation method, the 25 following polymers may be prepared, for example PVC, polylactides, polystyrene, polyvinylacetate, polybutadiene, polyacrylonitrile, polyvinylester, polyvinylether and copolymers thereof. Emulsion polymerised copolymers of methyl and/or ethyl esters of 30 acrylic and methacrylic acid are preferred. The molecular weight of the emulsion polymers should ideally be between 104 and 107. The carrier material may be recovered as a solid, e.g. by freeze drying, with the particles of polymer retaining their shape and size. 35 Matrix systems for transdermal administration generally comprise a backing layer which contains the active substance, a reservoir containing the active 236 2 6 substance (active substance matrix store) and means for securing it to the skin. The release of active substance is controlled either by a suitable choice of the polymer matrix - as disclosed 5 for example in European Patent 86997 - or by means of suitable membranes, as described for example in US Patents 3598122 and 3598123. In one embodiment, the system according to the invention contains a backing layer which is impervious to 10 the active substance, a polymer matrix containing the active substance, with 2 to 10% by weight of a weak base, a weak acid or a salt for adjusting the pH of the skin and means for securing the system to the skin. 15 preferably consists of an emulsion-polymerised polyacrylate. Systems of this kind are disclosed for example in published German Application 2920500, European Patent Application 209121 and European Patent 86997, the contents of which are hereby referred to. 2 0 Particularly preferred emulsion polymers are the copolymers based on the alkyl esters of acrylic and methacrylic acid. The general formula is wherein R1 = H, CH3 and R2 = H, C^-C^-alkyl C^-C^-alkyl-N (C^-C^-alkylJj. The average molecular weight is between 6 x 104 and The matrix which contains the active substance 25 [ch2-cr1-ch2-cr1]n coor2 coor2 30 1.6 x 107, the range between 104 and 106 being preferred. The following Eudragit® emulsion polymers E 30 D MW 800 000 R, = H, CH3, E 12,5/100 MW 150 000 35 r2 = ch2-ch2-n(ch3)2 ch3, cah9. L/S 100 MW 135 000 R, = CH3 R2 = H, CH3; 2 362 - 7 - made by Rohm GmbH of Darmstadt and mixtures thereof are preferred. In order to produce the embodiment described above having a matrix of an emulsion polymer, the following 5 procedure is used: The freeze dried latex is taken up in an organic solvent or mixture of solvents which is capable of dissolving both the drug and the polyacrylate. The additive for adjusting the pH on the skin is added, 10 either in finely divided form as a powder or, if the solvent is water-miscible, in the form of a solution or suspension in water. Examples of solvents include lower aliphatic alcohols, ethers, ketones, esters, hydrocarbons or halohydrocarbons, particularly those having a boiling 15 point below 100°C which evaporate easily. Mixtures of solvents may also be used. The viscosities of the starting solution can be varied by a suitable choice of solvent or solvent mixture. The films should normally have a thickness of about 50 to 200 /xm. The temperature 20 at which the solution dries to a film is normally from ambient temperature to, at most, the boiling temperature of the solvent or the solvent mixture used, although normally drying will be carried out at lowest possible temperatures owing to the instability of many 25 pharmaceutically active substances and the risk of bubble formation in the film. The film may be produced continuously or discontinuously. The films obtained are cut into suitable pieces or stamped out and packaged in the usual way for the production of transdermal 30 preparations, possibly by applying a supporting and/or covering layer to one side of the film which contains the active substance and by attaching an adhesive layer with a removable protective coating to the other side. It may be attached to the skin using an adhesive covering 35 plaster. In another embodiment in which the transdermal system contains a membrane for controlling the release of active substance, the additives for adjusting the pH are 23 6 2 8 - 8 - provided on or in the side of the membrane facing the skin. In a further embodiment, the transdermal system takes the form of a multi-chamber system, with one or 5 more active substances incorporated in separate chambers whilst according to the invention the additives for adjusting the pH are provided in other chambers. The additives may occur in discrete chambers, e.g. in the form of a gel, solution or suspension. 10 Irrespective of the nature of the matrix system, the additive for adjusting the pH may be contained in a separate layer on the side which is next to the skin. This layer may take the form of a tacky polymer, a non-tacky polymer, a gel, e.g. an agarose gel, in the form of 15 a (viscous) solution or in the form of small particles. It is not absolutely necessary for the separate layer containing the additive to cover the entire active substance matrix. The present invention also relates to a transdermal 2 0 system, free from active substance, in the form of a plaster for adjusting the pH on the skin surface, in which the plaster contains apertures. These plasters may be used as under-plasters for placing under any plaster which contains active substance, e.g. in order to improve 25 the optimum flux rate of existing systems. In this case, the active substance is chiefly diffused through the surface of the skin which is not covered by the under-plaster. In another embodiment of an under-plaster according 3 0 to the invention containing no active substance, this may also be constructed so as to cover the skin completely, provided that neither its thickness nor its composition cause it to interfere with the diffusion of the active substance from the plaster containing the active 35 substance. This is the case, for example, with thin polyacrylate films. The composition of the under-plaster according to the invention with regard to the polymer (matrix) and the 23 6 2 - 9 - additive for adjusting the pH is analogous to that of the systems containing active substances described hereinbefore. In another embodiment, the transdermal system 5 contains, on the side facing the skin, small needles which pass through the stratum corneum and thus allow drugs to diffuse, unobstructed, through the pin pricks. (The "mosquito" system). The salts required keep the active substances in solution, on the one hand, so that 10 they can penetrate through the stratum corneum into the epidermis without crystallising out, but by a suitable choice of pH, in the acid buffered range, also prevent the growth of bacteria, so as to avoid the use of preservatives on the skin which may cause reactions of 15 intolerance. Plasters of this type for transdermal use are described for example in DE-OS 2305989. The graph below shows the permeability P of clenbuterol through human skin (function A); P is given in [cm/sec]. Curve B illustrates the water solubility of 20 the substance depending on the pH value [mg/ml]. Curve C shows the flux rate of clenbuterol over a wider pH range. (The right-hand ordinate in the graph is shown logarithmically). 25 2~ [jig/cm . h] 3 5' 7 9 PH 23 6 2 - 10 - The invention will now be more particularly described with reference to the accompanying drawings, which are by way of example only and in which: 5 Fig. 1 of the drawings shows a plan view of a plaster 1 according to the invention. By contrast to what is shown in the drawing, the plaster may just as easily be rectangular or circular. Fig. 2 shows the cross section of a preferred 10 embodiment of the plaster 10, in which the active substance 21 and the additive 22 for adjusting the pH are uniformly distributed in a polymer matrix. The protective film 30 is removed before use so as to expose the adhesive surface 31. 15 Fig. 3 shows another embodiment of the plaster 10, in which the release of active substance is controlled by a membrane 33. The additive 22 is contained in a separate layer 34. This drawing does not show the protective film 30. 20 Fig. 4 shows a similar embodiment of the plaster 10, but with the layer 34 consisting of a tacky polymer which contains the additive 22. Fig. 5 shows a cross section through a plaster which has on its underside small needles for penetrating the 25 topmost layer of skin. The polymer matrix 20 contains the active substance 21 and the additive 22. The flattened outer sides 3 5 of the plaster contain, on the underside, an adhesive layer 31 for fixing to the skin. The examples which follow are intended to illustrate 30 the invention. Preparation Example 1 Preparation of clenbuterol-Eudragit NE 30 D solution: 35 Acetone 1734 mg is placed in a heatable container with an airtight seal, with stirring, and Clenbuterol 21 mg 11 23fi2fiC) and Citric acid are slowly added thereto, with stirring. Eudragit NE 30 D 4 34 mg 21 mg 5 is added. The heater is closed and heated to 40°C with stirring. At this temperature, stirring is continued until a homogeneous solution has formed. The solution should be free from clusters. The viscosity of the 10 solution should be between 3000 and 4000 mPas. The heated solution is applied by means of a direct coating apparatus consisting of applicator means, heating channel and cooling means. A fixed blade (doctor blade) is arranged at right angles to the direction of advance in 15 the applicator means.. In front of the blade, the viscous acetone solution prepared as described above is applied to a carrier film. The acetone in the cast film is evaporated either by the ambient temperature or by means of a heating channel. 20 The coated carrier strip is cooled and then wound onto a film. Pieces of any desired size may be stamped out. The pieces are stuck into a covering plaster and can then be stuck onto the patient. 2 5 Preparation Example 2 Preparation of the clenbuterol-Eudragit NE 30 D solution: Acetone 1734 mg 30 is placed in a heatable container, with an airtight seal, with stirring and Clenbuterol and Sodium carbonate 21 mg 21 mg V * 7 JUNJ99tr 2362 8 10 - 12 - are slowly added thereto with stirring. Eudragit NE 30 D 434 mg is added. Processing is continued as described in Preparation Example 1, except that a suspension is formed instead of a clear solution. The following Examples illustrate the administration and the effect of pH: Example 1 Permeability of pH-modified clenbuterol controlled percutaneous applications (CPA) through human skin: 15 Composition of the CPA's: pH 10.0 pH 3.5 Clenbuterol 5 % 5 % Citric acid 5 % Na2C03 5 % 20 Polymethacrylate 90 % 90 % Eudragit* E 30 D A Franz cell was used as the release apparatus. This is a conventional method of testing the release of 25 drugs from pharmaceutical formulations. Samples were taken after 24 hours and 48 hours and the clenbuterol content was determined. 15 236 280 - 13 - pH-value 3.5 pH-value 10.0 Cell 1 2 3 12 3 Clenbuterol 3.48 0.65 2.64 7.8 11.44 9.84 diffusion after 24 hours in fx g/cm2 Clenbuterol 5.52 1.69 6.04 21.7 27.3 24.2 diffusion 10 after 48 hours in fj,g/cm2 It is clear that a higher diffusion rate is found at an alkaline pH than at an acid pH. Example 2 Fig. 6 shows results regarding the pH of the skin surface determined underneath the system on the skin 20 after 5 days' wearing, using a surface pH electrode. The systems tested differ in their concentration of citric acid in a polymethacrylate matrix. It is clear that only a citric acid concentration of more than 1% can bring about any significant change in the surface pH of the 25 skin. Example 3 Fig. 7 shows surface pH levels of drug-containing 30 controlled percutaneous applications (CPA's) of basic active substances which were changed by the addition of 5% citric acid or Na2C03. As a comparison, the surface pH found without the addition of salts or ionic substances was also determined. It is clearly apparent that the pH 35 can be varied both to basic pH levels and to acid pH levels. 236 2 - 14 - Example 4 Fig. 8 shows the pH on the skin under a transdermal therapeutic system applied thereto and worn for 6 days. The pH adjustments on the surface are clearly shown. The pH value selected is maintained on the skin for this period. </div>

Claims

<div class="application article clearfix printTableText" id="claims"> - 15 - 231)280 WHAT WE CLAIM IS:

1. A transdermal therapeutic delivery system comprising a plaster having a backing layer impervious to 5 a therapeutically active substance, a reservoir of active the backing layer and the skin and a means for securing the plaster on the skin, and in which at least one pharmacologically acceptable additive capable of 10 adjusting the pH of the skin surface to a desired predeterminable value is present.

2. A delivery system as claimed in claim 1 in which the pharmacologically acceptable additive comprises a 15 weak base, a weak acid, one or more inorganic or organic salts which form a buffer system with the skin surface, or a buffer system, or mixtures thereof, capable of providing a pH of from 3 to 10. 20

3. A delivery system as claimed in claim 1 or claim 2 in which the active substance and additive are provided in a polymer matrix.

4. A delivery system as claimed in claim 3 wherein 25 the polymer matrix is formed from an emulsion-polymerised polyacrylate.

5. A delivery system as claimed in either of claims 3 to 4 wherein the additive is present in an amount of 30 from 2 to 10% by weight based on the weight of active ingredient-containing polymer matrix.

6. A delivery system as claimed in any one of claims 1 to 5 wherein the active substance is 35 clenbuterol. substance situated, or adapted to be situated, between

7. A transdermal therapeutic delivery system substantially as hereinbefore described and with reference to the Examples. - 16 -

8. A method for the preparation of a transdermal therapeutic delivery system which comprises bringing into admixture in solution in an organic solvent, a therapeutically active substance, a pharmacologically 5 acceptable additive capable of adjusting the pH of the skin surface to a desired predeterminable level and a polymer, evaporating the solvent to form a polymer film containing said substance and said additive, said film being adapted to be provided with or used in conjunction 10 with a water-vapour-impervious backing layer and a skin securing layer.

9. A method as claimed in claim 8 substantially as hereinbefore described and with reference to the 15 Examples. BOEHRINGER INGELHEIM INTERNATIONAL GMBH by their Attorneys BALDWIN, SON & CAREY ■v 7 APR 1994 </div>